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Atherosclerosis is a systemic disease of the intermediate and large arteries that progress for decades before it is diagnosed. 
Although some may never experience any sign and symptoms of 
disease, in most people atherosclerosis eventually manifests with 
acute or chronic symptoms of poor organ perfusion (eg, angina, 
claudicatio intermittens). Acute disease manifestations, such 
as myocardial infarction and stroke, may be life-threatening.1 
Therefore, early diagnosis and treatment is crucial.
Please see https://www.ahajournals.org/atvb/atvb-
focus for all articles published in this series.
Postmortem pathological studies have provided signifi-
cant insights on the atherosclerotic plaque phenotypes linked 
to different manifestations of disease.2 Such studies have 
spurred high interest in developing and validating diagnostics 
to identify and characterize at-risk plaques noninvasively and 
in vivo and improve the stratification of patients with cardio-
vascular disease.
Magnetic resonance imaging (MRI) of the arterial vessel 
wall is uniquely positioned to address these diagnostic needs.3 
Since MRI does not deliver any ionizing radiation, it is well 
suited for repeated, longitudinal examinations to follow-up 
the progression of atherosclerotic plaque. Its excellent soft tis-
sue contrast and the ability to discriminate not only the vessel 
lumen but also the vessel wall in high resolution allow meas-
uring plaque size and thickness with accuracy. Furthermore, 
MRI-based phenotyping of vulnerable plaque components, 
such as intraplaque hemorrhage, lipid-rich necrotic core, and 
thin fibrous cap, can be performed based on their appearance 
in different image weightings (eg, T1, T2, and proton den-
sity [PD]). These kind of techniques have been demonstrated 
to improve risk assessment of subsequent cardiovascular 
events4–9 and to be useful as surrogate imaging markers of 
drug efficacy.10–15
However, several challenges still need to be addressed be-
fore these key features of vessel wall MRI can be fully lever-
aged to diagnose and characterize atherosclerotic disease in 
clinical settings.
First, vessel wall MRI requires imaging with high spatial 
resolution to accurately quantify atherosclerotic plaque size 
and thickness and identify plaque components even in rela-
tively small arteries, such as the ones of the intracranial or 
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Abstract—Atherosclerosis is a prevalent disease affecting a large portion of the population at one point in their lives. There 
is an unmet need for noninvasive diagnostics to identify and characterize at-risk plaque phenotypes noninvasively and in 
vivo, to improve the stratification of patients with cardiovascular disease, and for treatment evaluation. Magnetic resonance 
imaging is uniquely positioned to address these diagnostic needs. However, currently available magnetic resonance 
imaging methods for vessel wall imaging lack sufficient discriminative and predictive power to guide the individual 
patient needs. To address this challenge, physicists are pushing the boundaries of magnetic resonance atherosclerosis 
imaging to increase image resolution, provide improved quantitative evaluation of plaque constituents, and obtain 
readouts of disease activity such as inflammation. Here, we review some of these important developments, with specific 
focus on emerging applications using high-field magnetic resonance imaging, the use of quantitative relaxation parameter 
mapping for improved plaque characterization, and novel 19F magnetic resonance imaging technology to image plaque 
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coronary circulation. Ideally, imaging should be performed 
using 3-dimensional (3D) techniques, with extended coverage 
along a vascular territory for a comprehensive assessment of 
disease.16,17 Imaging voxels should have submillimetric 3D 
isotropic resolution to better visualize and quantify disease in 
tortuous vessels, while minimizing partial volume artifacts. 
Unfortunately, because of intrinsic magnetic resonance (MR) 
signal limitations, high-resolution 3D acquisitions are very 
lengthy at the most commonly used field strengths of 1.5 T 
and 3 T, not well tolerated by patients, prone to pulsatility 
or bulk motion artifacts, and affected by relatively poor sig-
nal-to-noise. Up to now, spatial resolutions of 0.6 to 0.7 mm 
(isotropic) have been achieved with a good signal-to-noise and 
acquisition times tolerable for patients.16,17 However, this may 
not be sufficient to quantify disease burden and characterize 
plaque phenotype in the intracranial and coronary arteries.
Furthermore, the quantification of different plaque com-
ponents related to vulnerability (Figure 1A) currently relies 
on their identification and segmentation on T1-, T2-, and 
PD-weighted images.4,18 Although certainly valuable in 
patients with established disease, this approach does not allow 
for the screening and assessment of the progression of athero-
sclerosis in patients with less advanced lesions. Alternatively, 
plaque phenotype can be better characterized with the use of 
MR contrast agents, such as gadolinium-based agents or iron 
oxides to quantify, respectively, plaque permeability or the 
presence of inflammatory cells (see also Quantifying Contrast 
Agent Dynamics).19 However, safety concerns regarding their 
long-term tissue accumulation may limit the use of these agents 
in future clinical practice.20,21 Furthermore, since their plaque 
accumulation can only be measured indirectly by quantifying 
resulting changes in tissue T1 and T2(*), these approaches may 
be affected by limited sensitivity and specificity.
Several technological strategies are currently being 
explored to surpass these challenges and improve the charac-
terization of atherosclerosis by MRI. Among these numerous 
efforts, in this review, we will specifically focus on recent 
developments aimed at (1) improving the quantification of 
plaque burden by achieving higher spatial resolution and sig-
nal-to-noise at 7 T (ultra-)high field, (2) advancing the charac-
terization of early or less advanced plaques using quantitative 
T1 and T2(*) mapping, and (3) directly quantifying plaque in-
flammation using fluorine (19F) MRI.
High Magnetic Field
Vascular MRI may significantly benefit from the use of 
high magnetic field strength scanners (7 T and higher). The 
increased signal-to-noise ratio (SNR) associated with higher 
field MRI can be used to increase spatial resolution, needed 
to accurately quantify plaque size and to identify relevant vul-
nerable plaque components. However, to fully benefit from 
the intrinsically higher SNR, there are several challenges as-
sociated with high magnetic fields that need to be overcome. 
Since clinical 7 T scanners currently lack a body coil, local 
transmit coils are required. This may result in inhomogeneous 
B1 transmit fields, particularly when coil geometry is com-
plicated by anatomic constraints such as the carotid arteries 
in the neck. Furthermore, optimal fat suppression, efficient 
blood saturation, and—for the brain—cerebrospinal fluid 
(CSF) suppression are essential to appreciate the vessel wall 
and (intra-) plaque components which can also be negatively 
affected by B1 inhomogeneities.
Carotid Arteries
Thus far, there have been only a handful of studies demon-
strating feasibility of human carotid artery vessel wall imaging 
at 7 T. The neck anatomy requires a custom radiofrequency 
coil design with transmit and receive capabilities. After some 
preliminary conference reports on prototype 7 T carotid ar-
tery coils,22–24 a first journal article on a 7 T transmit/receive 
radiofrequency array for imaging of the carotid arteries was 
published by Kraff et al25 in 2011. Their design consisted of a 
2×4-channel transmit/receive array to cover both sides of the 
neck. The in vivo imaging protocol was applied to a healthy 
person and a patient with a known ulcerating plaque with 50% 
stenosis and consisted of 3D-FLASH (fast low angle shot) 
bright-blood imaging as well as a PD/T2-weighted turbo-spin-
echo sequence to depict the vessel wall and plaque. The images 
confirmed the extent of stenosis in the patient and revealed the 
ulcerating plaque. This study demonstrated that (ultra-)high 
field in vivo MRI of carotid artery plaque is feasible and has 
clinical potential to reveal plaque components. However, there 
are still considerable technical challenges associated with 7 T, 
including specific absorption rate restrictions, inhomogeneous 
transmit fields, and high field–related artifacts.
Kröner et al26 provided a first direct comparison of 3 T 
and 7 T carotid imaging to evaluate whether the advantages 
of the expected gain in SNR and image resolution at 7 T out-
weigh the increased technical difficulties associated with im-
aging at high field. Both carotid arteries of healthy volunteers 
were imaged with a 2× single-loop transmit/receive coil for 7 
T and a 2× single-loop receive-only coil for 3 T. T1-weighted, 
T2-weighted, and time-of-flight bright-blood imaging proto-
cols with comparable settings at 3 T and 7 T resulted in signif-
icantly improved vessel-wall SNR and lumen-wall CNR for 7 
T. Comparable accuracy was achieved for luminal and vessel 
wall areas.
Koning et al27 introduced a different coil design for 7 T 
carotid MRI consisting of separate transmit and receive array 
coils. The advantage of separating transmission from recep-
tion is that both can be individually tailored for optimal per-
formance. The receiver coil consisted of a 2×15-channel array 
for both sides of the neck, which can be placed near the carotid 
arteries for optimal sensitivity and parallel imaging perfor-
mance. The 2-channel transmission coil comprised radiative 
antennas and were placed more distant from the neck on a 
flexible neck pillow filled with deuterium-oxide as a dielectric 
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substrate. The design offered reasonable transmit homoge-
neity while preventing high local energy deposition specific 
absorption rate associated with small transmission coils 
placed directly on the skin. The performance of this coil was 
evaluated in comparison to 3 T imaging in healthy subjects 
and patients with carotid stenosis.28 An average 2-fold gain 
in SNR was achieved at 7 T compared with 3 T. The coil was 
also tested in a cohort of patients with symptomatic stenosis 
(>70%) of the internal carotid artery, scheduled for endarter-
ectomy.29 The 7 T MRI scans enabled adequate determinations 
of vessel lumen and vessel wall areas. However, essentially 
no correlations were found between vessel wall contrast and 
histological findings of the excised plaque, apart from ab-
sence of signal with calcifications. This shows that merely the 
gain in SNR associated with the use of 7 T does not guarantee 
improved plaque composition characterization.
High resolution and good definition of the vessel wall and 
plaque are essential for accurate plaque size and composition 
assessment. Currently, a voxel size of 0.4×0.4×2 mm by 3D 
carotid artery black-blood T2-weighted imaging was dem-
onstrated by Calcagno et al30 using a 2×4-element transmit/
receive array. Adequate suppression of the bright signal from 
blood in the vessel lumen is required to prevent bleeding of 
blood signal into the artery wall and partial volume contam-
ination. However, the use of local transmission coils limits 
efficient inflowing blood suppression, particularly in the ca-
rotid arteries where blood flow is high. To tackle this problem, 
Papoutsis et al recently introduced a carotid artery imaging coil 
consisting of a 2×2-channel transmission array combined with 
a 2×2-channel receiver.31 The receiver coils and 2 transmission 
elements were placed at the level of the carotid bifurcation. 
The other 2 transmission elements were placed at the lower 
part of the neck. The extended coverage of the radiofrequency 
transmission coils ensured efficient black-blood imaging with 
good wall/lumen definition using DANTE (delay alternating 
with nutation for tailored excitation) preparation pulses for 
blood signal suppression. Although 7 T has demonstrated po-
tential for improved 3D high-resolution vessel wall imaging, 
resolving certain anatomic details, such as the thin fibrous cap 
in vulnerable plaques, may still be beyond the capabilities of 
the current technology. Furthermore, pulsatile motion artifacts 
which become apparent at the higher 7 T image resolutions 
Figure. Emerging magnetic resonance imaging (MRI) techniques for atherosclerosis imaging. A, Schematic of an atherosclerotic plaque in an artery wall. B, 
High-field (7 T) MRI of intracranial vessels in a symptomatic patient. Arrowheads indicate locations of focal thickening of the vessel wall. Adapted from Harte-
veld et al38 with permission. Copyright ©2019, Wolters Kluwer Health, Inc. C, Axial slice from a 3D quantitative T1 and T2 mapping acquisition of the carotid 
of a patient with a large atherosclerotic plaque and significant stenosis. Plaque and vessel wall T1 and T2 values are color coded according to the scales next 
to the images. Lower T1 and slightly elevated T2 values in the plaque are indicative for intraplaque hemorrhage. D, Preclinical 19F-MRI of the aortic arch of a 
control mouse and an atherosclerotic ApoE−/− mouse. Top, Ex vivo photographs of the excised aortas. Arrows indicate plaque locations. Bottom, Ex vivo 19F-
MRI of the aortas. The 19F signal intensity is overlaid in orange/red colors on the regular 1H-MRI. Arrows indicate 19F signals in the plaques. Right, 3D rend-
ering of the mouse aorta with 19F signal. Adapted from van Heeswijk et al65 with permission. Copyright ©2018, Radiological Society of North America. ACA 
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will require further optimization, while preserving reasonable 
imaging times. For example, although current high-resolution 
3D sequences are typically used without the use of cardiac 
gating, this may become beneficial beyond a certain spatial 
resolution (eg, <0.5 mm).
MRI of Intracranial Vessels
Similar to carotid atherosclerosis, disorders of the vasculature 
in the brain pose a significant risk to physical and cognitive 
health. Because of their smaller sizes, imaging of the intracra-
nial vessel wall may especially benefit from improved resolu-
tion facilitated by the higher SNR associated with 7 T.32 Since 
the advent of 7 T MRI scanners, imaging of the brain has been 
a principal application and multiple vendor- and third-party 
coil designs for optimized radiofrequency transmission and 
receive sensitivity are readily available for intracranial angi-
ography and vessel wall imaging.33
A particular requirement for accurate intracranial vessel 
wall imaging is that both the signal from the blood and the 
CSF lining the arteries needs to be suppressed. Blood suppres-
sion strategies that have been applied to the carotid arteries 
may also be applied to suppress the blood signal in the brain. 
These include double-inversion recovery34 as well as motion 
sensitized prepulses such as MSDE (motion sensitized driven 
equilibrium)35 and DANTE.36 Problems may occur in regions 
with slow flow, for example, near the vessel wall and in aneu-
rysms, where motion sensitization becomes ineffective, lead-
ing to incomplete blood suppression and overestimation of 
the vessel wall thickness. Suppression of CSF is even more 
challenging since CSF flow is slow and the long T1 of CSF, 
particularly at 7 T, renders inversion-recovery methods to null 
the signal very time-inefficient.
Despite these technical challenges, several groups have 
successfully pioneered intracranial vessel wall imaging at 7 
T (Figure 1B) in healthy subjects and patients with differ-
ent vascular conditions.18,36–42 For example, Harteveld et al41 
studied the presence and location of intracranial vessel wall 
lesions in patients with recent posterior cerebral circulation 
ischemia compared with nonsymptomatic controls, using in-
tracranial vessel wall MRI at 7 T. Although no large differ-
ences in lesion burden between both groups were observed, 
this study nevertheless showed that the technical challenges 
involved with 7 T MRI can be overcome to provide detailed 
characterization of the intracranial vessel status. Although not 
primarily focused on imaging the intracranial vessels, a re-
cent study by Obusez et al18 included more than 100 patients 
with a range of neurological pathologies and showed that 7 T 
provided increased conspicuity for brain lesions and revealed 
new lesions not seen on 1.5 T and 3 T. Certainly, high-field 
MRI of vessel walls has the potential to alter diagnosis and 
treatment in the (near) future.
Relaxation Time Mapping
Plaque Component Characterization
MR contrast between different tissues is mainly caused by 
their different PD or relaxation time constants (T1 for the 
longitudinal relaxation and T2 for the transverse relaxa-
tion). Developed already in the late 90s,43,44 2D multicontrast 
MRI protocols consisting of T1-, T2-, PD-weighted black-
blood imaging and time-of-flight angiography are still the 
standard (pre)clinical research tool for plaque characteri-
zation. However, even after 3 decades, these protocols are 
not part of routine clinical decision-making in patients with 
suspected vulnerable plaques. This may partly be explained 
by the fact that plaque component characterization based 
on these acquisitions has been mostly qualitative by nature, 
where the presence of specific plaque components has been 
determined by visual inspection of the relative signal inten-
sities between the plaque and surrounding (muscle) tissue. 
This approach can easily lead to large intraobserver varia-
bility as well as inconsistent clinical conclusions, depending 
on the choice of sequence parameters.45,46 In the last decades, 
however, many new acquisitions and analysis pipelines have 
been developed with the potential for a quantitative and user-
independent plaque component classification, as described 
further in this section.
A promising new development toward robust plaque phe-
notyping is the recent introduction of quantitative parameter 
mapping techniques, aimed at quantifying plaque T1 and 
T2 relaxation times, which may more directly reflect plaque 
composition (Figure 1C). Quantitative relaxation mapping 
has already started to replace qualitative imaging sequences 
in cardiac imaging, which has facilitated the standardization 
of protocols and threshold values to help clinicians diagnose 
cardiac pathologies.47 Although an easy translation of such 
methods to atherosclerosis imaging has been complicated 
by the need for robust blood suppression, recent studies have 
applied, with success, these quantitative methods to vessel 
wall imaging, especially in the carotid arteries.
The first robust quantitative vessel wall MRI protocol was 
presented by Biasiolli et al,48 in which T2 quantification of ca-
rotid plaques was achieved by a 2D cardiac gated multi-echo 
spin echo sequence, preceded by a double-inversion blood 
suppression preparation. This method provided solid T2 refer-
ence values for different plaque components, such as lipid-rich 
necrotic core (T2=37±5 ms), fibrous tissue (T2=56±9 ms), 
and intraplaque hemorrhage (T2 >90 ms). Moreover, the tech-
nique of T2 mapping to estimate the lipid area within plaques 
discriminated symptomatic and asymptomatic patients,49 as 
well as detected a reduction of lipid content within the plaque 
after 3 months of statin treatment.50
The addition of T1 mapping may further improve iden-
tification of important biomarkers of plaque vulnerability, 
such as a fresh intraplaque hemorrhage.48 Two protocols for 
T1 mapping have recently been introduced, either based on 
variable flip angle steady-state51 or inversion-recovery pre-
pared imaging sequences.52,53 These protocols were designed 
for combined T1 and T2 estimation and can be applied at 
3D isotropic (0.7–0.8 mm) resolution. While Coolen et al51 
mainly focused on achieving efficient blood suppression for 
all individual images used for T1 and T2 quantification, this 
was not possible for the method recently proposed by Qi et 
al53 On the contrary, the latter method used efficient 3D ra-
dial k-space trajectories making imaging times significantly 
shorter. Unfortunately, T1 mapping has not been applied so far 
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The accuracy of quantitative T1 and T2 values increases 
when more data points (ie, with more inversion or echo times) 
are acquired. This may require protocols that exceed clini-
cally feasible imaging times. In this respect, the introduction 
of advanced iterative reconstruction algorithms, such as com-
pressed sensing and machine learning allows for reductions in 
the amount of data (and hence scanning time) necessary for 
image reconstruction, and are now increasingly used in clin-
ical quantitative vessel wall imaging.54–56
Quantifying Contrast Agent Dynamics
The use of untargeted contrast agents in MR atherosclerosis 
imaging can be categorized into roughly 2 approaches. The 
first is aimed at measuring plaque inflammation using T2* 
shortening by iron oxide particles and, the second approach 
aims to visualize plaque permeability by dynamic contrast-
enhanced MRI using untargeted gadolinium-based MR con-
trast agents. For both applications, the need for quantitative 
readouts is eminent.
Iron oxide nanoparticulate contrast agents are taken 
up by phagocytic cells, and their cellular accumula-
tion can be detected as signal loss by T2(*)-weighted MRI. 
The ATHEROMA trial (Atorvastatin Therapy: Effects on 
Reduction of Macrophage Activity)15 was the first prospec-
tive MRI study to show the effects of statin therapy on ca-
rotid plaque inflammation using iron oxide contrast agents 
in combination with T2*-weighted imaging. However, it 
was also criticized because of the qualitative nature of the 
methodology.57 This has inspired other researchers to develop 
quantitative T2* mapping using 2D58,59 or 3D54,55 black-blood 
multigradient-echo sequences to improve scan-rescan re-




) as a 
semiquantitative measure of iron particle accumulation. For 
these protocols, the earlier mentioned compressed sensing 
techniques have yet to be applied.
Although considerable success has been achieved with 
iron oxide contrast agents, it remains nontrivial to detect 
and particularly quantify inflammation from the iron oxide–
induced signal voids. Furthermore, once present in the plaque, 
the iron oxide–induced contrast changes hamper the quantifi-
cation of plaque composition by traditional multicontrast MRI 
(eg, T1 and T2) and dynamic contrast-enhanced imaging with 
gadolinium contrast to evaluate plaque permeability.
The quantification of plaque permeability using analysis 
of signal intensity time curves after contrast agent injection 
comes with many limitations,19 mostly related to incorrect 
assumptions of signal linearity of the arterial input function 
and because of the assumption of a single precontrast T1 de-
spite obvious field inhomogeneity in the plaque. Recently, 
Wang et al60 have presented groundbreaking work to over-
come these limitations by the introduction of a quantitative 
T1 mapping dynamic contrast-enhanced sequence with a tem-
poral resolution as low as 500 ms. Key to achieving this un-
precedented speed is a sophisticated reconstruction method 
that involves a single reconstruction of the complete 5-dimen-
sional data matrix (3 spatial dimensions, saturation recovery, 
and dynamic scans) and exploiting the low-rank nature of this 
acquisition matrix.61 This protocol allows T1 mapping with 
high spatiotemporal resolution, providing the necessary data 
to correctly model the AIF (arterial input function) and plaque 
response curves for dynamic contrast-enhanced analysis.
Fluorine-19 Imaging
Imaging of Vascular Inflammation
Macrophages play a key role in plaque rupture and thrombo-
genicity. As such, macrophage density is considered an im-
portant contributor to plaque development and subsequent 
vulnerability to rupture.62 Plaque uptake of the positron emis-
sion tomography tracer 18F fluorodeoxyglucose has been 
widely used as a noninvasive and sensitive surrogate marker 
of macrophage density and inflammation in atheroscle-
rosis.63,64 However, imaging of fluorodeoxyglucose of vascular 
origin is challenging in tissues with high background meta-
bolic activity, such as in the heart and the brain. Also, the short 
half-life time of 18F (≈110 min) prevents monitoring of mac-
rophage migration and activity over longer periods of time.
19F-MRI
A promising alternative strategy towards the realization of 
clinically feasible inflammation and atherosclerosis im-
aging is the use of fluorinated nanoparticles.65,66 Fluorinated 
nanoparticles contain the stable fluorine isotope 19F, which has 
a spin ½ and a gyromagnetic ratio of 40.08 MHz/T, result-
ing in 83% the sensitivity of 1H.67 The human body contains 
negligible amounts of 19F, which implies that any detected 
19F-MRI signal originates from the nanoparticles with little 
to no background, clearly benefiting quantification purposes. 
Moreover, unlike the radioactive 18F isotope used in fluorode-
oxyglucose-positron emission tomography, the 19F signal does 
not decay, which enables detection and tracking of the label 
over extended periods of time. Similar to iron oxides, fluori-
nated nanoparticles can be tailored by changing size or surface 
composition to stimulate phagocytosis by inflammatory cells, 
with the advantage that their accumulation is directly propor-
tional to the 19F-MRI signal and does not interfere with 1H 
image contrast. This means that fluorinated nanoparticles can 
be used in combination with regular T1- and T2-weighted 1H 
MRI, and other contrasts.
The general working hypothesis of imaging of atheroscle-
rosis by 19F-MRI involves phagocytosis of the nanoemulsions 
by circulating monocytes and macrophages on intravenous 
injection. The 19F-filled monocytes and macrophages subse-
quently traffic to the sites of inflammation, where they can be 
imaged by 19F-MRI once present in sufficiently high concen-
trations. The 19F signal also accumulates in the body’s reposi-
tories of immune cells, such as in the liver (Kupffer cells), the 
lymph nodes, and in the bone marrow.65 Clearance is via the 
lungs and the liver.
In the context of inflammation imaging, most 19F-MRI has 
been performed using nanoemulsions filled with perfluorocar-
bons. The liquid hydrophobic perfluorocarbon core in these 
nanoemulsions is surrounded by a lipid monolayer in which 
additional targeting ligands (or even gadolinium-contrast 
agents) can be incorporated.66,68 Different perfluorocarbons are 
available, including perfluorodichlorooctane, perfluorodeca-
lin, perfluoro 15-crown-5 ether, and perfluorooctyl bromide. 
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of 3 to 6 hours, depending on size (typically 100–400 nm) 
and species.69 This imaging technique has great potential and 
has been explored, so far, in a variety of preclinical studies on 
Alzheimer disease,70 lung imaging,71 cancer,72,73 (re)stenosis,74 
cell tracking,75,76 myocardial infarction and stroke,77,78 and in-
flammatory bowel disease.79
Fluorine Imaging and Atherosclerosis
The first use of perfluorocarbon nanoparticles for detecting 
ex vivo atherosclerotic plaques was reported in 2004.80 A first 
convincing in vivo demonstration of plaque inflammation im-
aging by 19F-MRI, albeit not in humans but in a mouse model, 
is only as recent as 2015.65 A perfluorocarbon-containing 
nanoemulsion was injected in ApoE−/− mice, a well-known 
mouse model of atherosclerosis, and imaged up to 14 days 
after injection. The 19F signal was observed in the aortic arch, 
the carotid arteries, and the brachiocephalic artery, known 
regions where atherosclerotic plaques develop in this mouse 
model (Figure 1D). Ex vivo 3D visualization of segmented 
high spatial resolution 3D MRI of the atherosclerotic plaques 
in the excised aortic arches and their branching vessels con-
firmed that the source of the 19F was indeed from within the 
atherosclerotic vessel wall. Importantly, immune-fluorescent 
staining for macrophages and perfluorocarbon demonstrated 
the colocalization of both fluorescent signals, confirming that 
the 19F signal particularly originated from the macrophages 
located within the atherosclerotic plaques. However, cells that 
were not macrophages also absorbed perfluorocarbon, sugges-
tive that other cell types are also capable of phagocytosis of 
these perfluorocarbon nanoparticles. Future work will be nec-
essary to study the specificity of 19F phagocytosis by immune 
cells and whether these can be of prognostic value.
Depending on their size, perfluorocarbon nanoemulsions 
may also passively diffuse into the intimal space of the plaque 
or inflammatory cells located there. In the early stages of ath-
erosclerosis, the proinflammatory status of the vasculature 
causes the endothelial layer to be weakened or leaky, resulting 
in a higher permeability of macromolecules through the en-
dothelial barrier. Zhang et al81 investigated this phenomenon 
in rabbits fed with a high-fat diet for up to 14 months. Twelve 
hours after injection of emulsions with varying nominal diam-
eter, ex vivo 19F-MRI scans revealed the features of endothe-
lial barrier disruption and rapid penetration of nanoparticles, 
even up to micron size, was observed far into the intima of 
later-stage, but not early-stage, plaques. Thus, apart from 
active transport of perfluorocarbon emulsions into the plaque 
by macrophages, also passive accumulation might attribute to 
the 19F-signal in the plaques. It therefore remains to be further 
investigated how specific and quantitative vascular inflamma-
tion imaging by 19F-MRI technology is.
Technical Considerations
Although the intrinsic 19F-MRI detection sensitivity is close to 
the one of 1H and there is essentially no native 19F in the human 
body, it remains challenging to detect and quantify the 19F signal 
from low concentrations of nanoparticles. The actual detection 
sensitivity depends on many experimental factors, including 
the total acquisition time, number of averages, sequence type, 
image resolution, etc The detection sensitivity in mice is typi-
cally in the low millimolar range using sequences and hardware 
optimized for small animal imaging,82 resulting in reasonable 
acquisition times (≈10 min). Most 19F perfluorocarbon reso-
nances have relatively long T1 and T2 relaxation times,82 which 
favors 3D imaging with balanced SSFP and turbo-spin-echo 
sequences.83 In the case of perfluorocarbons, these relaxa-
tion times may also depend on temperature,82,84 magnetic field 
strength,84 and tissue oxygenation level.85 The introduction of 
new 19F compounds requires reassessment of the relaxation 
time properties and optimization of sequence parameters.
There are several exciting new developments in 19F-
MRI that make the technique even more attractive. Since the 
19F-agent accumulates at sites of active inflammation, the 
19F-signal will often be localized rather than dispersed. This 
can be exploited in modern image acquisition and reconstruc-
tion strategies such as compressed sensing86,87 to maximize 
the signal-to-noise per unit time or reduce acquisition times 
to clinically acceptable numbers. Moreover, different fluori-
nated compounds can be detected on the basis of differences 
in chemical shift and imaged independently from each other 
(ie, multiplexed) in the same imaging session, offering unique 
opportunities to image different populations of inflammatory 
cells in the same subject.88,89 One major concern for the trans-
lation of 19F-MRI into daily clinical practice is the long half-
life time of the particles, which can be up to several months 
for certain types of nanoemulsions.90
Summary and Future Outlook
In this article, we reviewed some of the important emerg-
ing MRI techniques for improved atherosclerosis imaging, 
namely (1) high spatial resolution, high signal-to-noise im-
aging at clinical 7 T, (2) quantitative T1/T2(*) mapping for 
improved plaque characterization, and (3) quantitative 19F in-
flammation imaging.
Technical challenges with field and transmit inhomogene-
ities, as well as patient discomfort, are currently still impeding 
the use of field strengths beyond 7 T.91 However, the general 
need for higher spatiotemporal resolution in vascular MRI 
may encourage the use of these higher field strengths. New 
techniques will have to be developed or optimized to deal with 
new prominent imaging artifacts emerging at higher spatial 
resolution, such as pulsatile vessel motion. Acquisitions in-
sensitive to (pulsatile) motion and sophisticated gating tech-
niques—developed to deal with cardiac motion when imaging 
the coronaries92—might also prove beneficial for carotid and 
intracranial artery imaging.
Protocols for quantitative relaxation time mapping of ath-
erosclerotic plaques in the carotid arteries are ready for clin-
ical use but need more extensive evaluation in large cohort and 
multicenter studies to establish their added value in compar-
ison to standard techniques. Finally, although the use of 19F 
MRI for plaque imaging is still in its infancy and currently 
limited to preclinical applications, it has several advantages 
(quantitative, no background, and multiplexing) that makes it 
a promising tool for in vivo plaque phenotyping.
While major advances in MRI of atherosclerosis have been 
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the quantification of plaque burden and characterization of 
vulnerable plaques, most of these techniques have yet to be 
translated into (routine) clinical practice. Successful clinical in-
troduction, however, relies on many factors. First of all, the new 
techniques and hardware (radiofrequency coils) need to become 
available across the different clinical scanner platforms and opti-
mized for scan time and ease-of-use. Protocols need to be vali-
dated for reproducibility. On-line postprocessing of raw image 
data has to be standardized and integrated in the workflow of 
data acquisition, (PACS [picture archiving and communication 
system]) storage, analysis, and viewing. Most importantly, more 
large-scale clinical research studies across ethnicity, sex, and 
age are needed to unequivocally demonstrate the added value of 
these techniques in the management of atherosclerotic disease.
In conclusion, the demand for personalized approaches 
in the era of precision medicine drives the need for nonin-
vasive diagnostics to identify and characterize at-risk plaque 
phenotypes noninvasively and in vivo. This will continue to 
stimulate research into more powerful atherosclerotic MRI 
protocols and present new opportunities for improved diag-
nosis and treatment of atherosclerosis.
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• There is an unmet need for noninvasive diagnostics to identify and characterize at-risk plaque phenotypes noninvasively and in vivo, to improve 
the stratification of patients with cardiovascular disease, and for treatment evaluation.
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tative evaluation of plaque constituents, and obtain readouts of disease activity such as inflammation.
• Emerging imaging technologies are high-field magnetic resonance imaging, the use of quantitative relaxation parameter mapping for improved 
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